{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"12"}],"units":"Participants"}],"description":"ORR is defined as sum of CR and PR rates, Response assessment for PTCL based on IWG criteria (Cheson 2007) and CTCL on mSWAT/Global assessment (ISCL/EORTC guideline).","groups":[{"description":"RP6530 administered 200 mg orally twice a day.","id":"OG000","title":"Dose escalation_Cohort 1_200 mg"},{"description":"RP6530 administered 400 mg orally twice a day.","id":"OG001","title":"Dose escalation_Cohort 2_400 mg"},{"description":"RP6530 administered 800 mg orally twice a day under fasting condition","id":"OG002","title":"Dose escalation_Cohort 3_800 mg (Fasting)"},{"description":"RP6530 administered 800 mg orally twice a day under fed condition","id":"OG003","title":"Dose escalation_Cohort 4_800 mg (Fed)"},{"description":"RP6530 administered 800 mg orally twice a day under fasting condition","id":"OG004","title":"Dose expansion_PTCL_800 mg (Fasting)"},{"description":"RP6530 administered 800 mg orally twice a day under fasting condition","id":"OG005","title":"Dose expansion_CTCL_800 mg (Fasting)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients were considered for efficacy analysis as per protocol only if they had one post treatment efficacy assessment at C3D1","reportingStatus":"POSTED","timeFrame":"8 months","title":"Overall Response Rate (ORR) With RP6530","type":"SECONDARY","unitOfMeasure":"Participants"}